
DermTech DMTK
Annual report 2023
added 02-29-2024
DermTech Total Non Current Liabilities 2011-2026 | DMTK
Annual Total Non Current Liabilities DermTech
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | - | 865 K | 5.03 M | 5.03 M | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 5.03 M | 865 K | 3.64 M |
Total Non Current Liabilities of other stocks in the Diagnostics research industry
| Issuer | Total Non Current Liabilities | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
Enzo Biochem
ENZ
|
4.6 M | - | -8.98 % | $ 14.8 K | ||
|
Centogene N.V.
CNTG
|
23.7 M | - | -6.23 % | $ 30.6 M | ||
|
Heska Corporation
HSKA
|
57.9 M | - | - | $ 1.31 B | ||
|
Celcuity
CELC
|
69.2 K | $ 89.18 | -3.56 % | $ 4.17 B | ||
|
Akumin
AKU
|
527 M | - | -17.87 % | $ 25.9 M | ||
|
Co-Diagnostics
CODX
|
574 K | $ 5.14 | -10.76 % | $ 6.84 M | ||
|
Fulgent Genetics
FLGT
|
2.26 M | $ 19.15 | -1.82 % | $ 589 M | ||
|
Castle Biosciences
CSTL
|
2.76 M | $ 21.36 | -1.13 % | $ 619 M | ||
|
Aspira Women's Health
AWH
|
3.49 M | - | -6.19 % | $ 10.5 M | ||
|
Accelerate Diagnostics
AXDX
|
134 M | - | -61.36 % | $ 2.46 M | ||
|
Guardant Health
GH
|
91.4 M | $ 127.58 | -4.12 % | $ 16 B | ||
|
Biocept
BIOC
|
11.3 M | - | -13.05 % | $ 7.29 M | ||
|
Interpace Biosciences
IDXG
|
10 M | $ 1.79 | 2.29 % | $ 7.92 M | ||
|
Oxford Immunotec Global PLC
OXFD
|
7.74 M | - | - | $ 562 M | ||
|
Illumina
ILMN
|
2.04 B | $ 162.64 | -3.23 % | $ 25.2 B | ||
|
CareDx, Inc
CDNA
|
17.9 M | $ 22.39 | -3.16 % | $ 1.19 B | ||
|
Chembio Diagnostics
CEMI
|
24.8 M | - | 0.22 % | $ 16.8 M | ||
|
Check-Cap Ltd.
CHEK
|
16 K | - | - | $ 9.42 M | ||
|
ICON Public Limited Company
ICLR
|
461 M | $ 149.96 | -1.86 % | $ 11.8 B | ||
|
HTG Molecular Diagnostics
HTGM
|
4.1 M | - | -20.0 % | $ 1.06 M | ||
|
Lantheus Holdings
LNTH
|
225 M | $ 102.59 | -0.22 % | $ 6.92 B | ||
|
Global Cord Blood Corporation
CO
|
2.53 B | - | - | $ 399 M | ||
|
Fluidigm Corporation
FLDM
|
131 M | - | 1.08 % | $ 308 M | ||
|
Genetic Technologies Limited
GENE
|
161 K | - | - | $ 7.1 B | ||
|
Genetron Holdings Limited
GTH
|
48.5 M | - | 0.12 % | $ 80.1 M | ||
|
NeoGenomics
NEO
|
435 M | $ 10.96 | -3.14 % | $ 1.4 B | ||
|
Charles River Laboratories International
CRL
|
2.35 B | $ 183.85 | -1.06 % | $ 9.11 B | ||
|
Natera
NTRA
|
124 M | $ 218.2 | -1.76 % | $ 29.8 B | ||
|
PRA Health Sciences, Inc.
PRAH
|
1.43 B | - | - | $ 10.7 B | ||
|
Pacific Biosciences of California
PACB
|
43.9 M | $ 1.46 | -10.74 % | $ 438 M | ||
|
Medpace Holdings
MEDP
|
73.8 M | $ 455.55 | -0.68 % | $ 13.1 B | ||
|
Mettler-Toledo International
MTD
|
1.61 B | $ 1 155.01 | -2.16 % | $ 23.8 B | ||
|
Exact Sciences Corporation
EXAS
|
981 M | - | - | $ 19.8 B | ||
|
Myriad Genetics
MYGN
|
107 M | $ 4.64 | -0.96 % | $ 430 M | ||
|
National Research Corporation
NRC
|
39.6 M | $ 19.52 | -1.14 % | $ 437 M | ||
|
Personalis
PSNL
|
639 K | $ 11.02 | -8.93 % | $ 983 M | ||
|
Koninklijke Philips N.V.
PHG
|
8.45 B | $ 26.17 | 0.67 % | $ 24.8 B | ||
|
Senseonics Holdings
SENS
|
163 M | $ 6.7 | -4.49 % | $ 280 M | ||
|
QIAGEN N.V.
QGEN
|
1.99 B | - | - | $ 10.6 B | ||
|
Soleno Therapeutics
SLNO
|
10.8 M | - | - | $ 2.69 B | ||
|
Biomerica
BMRA
|
1.57 M | $ 2.21 | 2.79 % | $ 5.08 M | ||
|
Laboratory Corporation of America Holdings
LH
|
7.82 B | $ 265.31 | 1.61 % | $ 22.1 B | ||
|
Twist Bioscience Corporation
TWST
|
4.56 M | $ 69.92 | -5.43 % | $ 4.18 B | ||
|
Thermo Fisher Scientific
TMO
|
22.5 B | $ 474.37 | -1.6 % | $ 179 B | ||
|
Trinity Biotech plc
TRIB
|
106 M | $ 0.72 | 5.2 % | $ 259 M | ||
|
Motus GI Holdings
MOTS
|
2.16 M | - | -34.28 % | $ 263 K | ||
|
Waters Corporation
WAT
|
1.28 B | $ 366.13 | -2.74 % | $ 21.8 B | ||
|
Neogen Corporation
NEOG
|
19.6 M | $ 8.99 | -1.48 % | $ 1.95 B | ||
|
Quest Diagnostics Incorporated
DGX
|
5.17 B | $ 200.67 | 2.3 % | $ 22.3 B |